Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | UGCG | Q16739 | 1/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21068740 | 0.85 | ADORA2A (0.32) | KDM4EALDH1A1ADORA2AMAPK14UGCG | |
| SCHEMBL21069120 | 0.82 | PTGS1 (0.34) | KDM4EALDH1A1L3MBTL1ADORA2AMAPK14 | |
| SCHEMBL21068671 | 0.79 | CNR2 (0.30) | KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL21068672 | 0.79 | CNR2 (0.30) | KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL21069019 | 0.79 | KDM4E (0.33) | KDM4EALDH1A1L3MBTL1ADORA2AMAPK14 | |
| SCHEMBL18952609 | 0.75 | PSEN1 (0.39) | KDM4EALDH1A1UGCG | |
| SCHEMBL21069140 | 0.70 | MAPK14 (0.41) | L3MBTL1ADORA2AMAPK14 | |
| SCHEMBL21069050 | 0.69 | KDM4E (0.32) | KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL21069051 | 0.69 | KDM4E (0.32) | KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL18952864 | 0.69 | PSEN1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109311878-B | Triazolopyridines as gamma-secretase modulators | 豪夫迈·罗氏有限公司 | 2022-05-24 | — | — | CN | disclosed |
| EP-3475279-B1 | TRIAZOLOPYRIDINES AS GAMMA-SECRETASE MODULATORS | HOFFMANN LA ROCHE (CH) | 2021-07-14 | — | — | EP | disclosed |
| EP-3475279-B1 | TRIAZOLOPYRIDINES AS GAMMA-SECRETASE MODULATORS | HOFFMANN LA ROCHE (CH) | 2021-07-14 | — | — | EP | disclosed |
| US-10875854-B2 | Triazolopyridines | HOFFMANN-LA ROCHE INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-10875854-B2 | Triazolopyridines | HOFFMANN-LA ROCHE INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20190194183-A1 | TRIAZOLOPYRIDINES | HOFFMANN-LA ROCHE INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190194183-A1 | TRIAZOLOPYRIDINES | HOFFMANN-LA ROCHE INC. (US) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194183-A1 | TRIAZOLOPYRIDINES | HTR2A, APP, PTGDR | KDM4E 4387/4885ALDH1A1 3356/4885L3MBTL1 966/4885 |
| US-10875854-B2 | Triazolopyridines | HTR2A, APP, PTGDR | KDM4E 4387/4885ALDH1A1 3356/4885L3MBTL1 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.